Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease

Bor Renáta and Farkas Klaudia and Fábián Anna and Bálint Anita and Milassin Ágnes and Rutka Mariann and Matuz Mária and Nagy Ferenc and Szepes Zoltán and Molnár Tamás: Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease.
PLOS ONE, 12 (3). e0172916. ISSN 1932-6203 (2017)

[thumbnail of 3220191_Bor_journal.pone.0172916_u.pdf]
Preview
Text
3220191_Bor_journal.pone.0172916_u.pdf - Published Version

Download (994kB) | Preview
Creators:
Bor Renáta MTMT
Farkas Klaudia MTMT
Fábián Anna MTMT
Bálint Anita MTMT
Milassin Ágnes MTMT
Rutka Mariann MTMT
Matuz Mária MTMT
Nagy Ferenc MTMT
Szepes Zoltán MTMT
Molnár Tamás MTMT
Item Type: Journal Article
Journal or Publication Title: PLOS ONE
Date: 2017
Volume: 12
Number: 3
Page Range: e0172916
ISSN: 1932-6203
Publisher: Public Library of Science (PLoS)
Faculty/Unit: Faculty of Pharmacy
Faculty of Medicine
Institution: University of Szeged (2000-)
Language: English
MTMT rekordazonosító: 3220191
DOI azonosító: https://doi.org/10.1371/journal.pone.0172916
Date Deposited: 2017. May. 29. 16:12
Last Modified: 2022. Sep. 26. 11:44
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/11479
Web of Science® Times Cited: 9 View citing articles in Web of Science®

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year